The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Coagulation factor-based compositions

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. 

Coagulation factor-based compositions is a key innovation area in biosimilars 

Coagulation factors also called clotting factors are blood proteins that help form blood clots on injuries to prevent bleeding. Coagulation factor concentrates are drugs used to manage bleeding in blood clotting disorders such as Haemophilia or Von Willebrand Disease. They can control, prevent, and decrease the frequency of bleeding episodes and prevent bleeding during surgery, by the activation of the prothrombin complex which induces clotting of blood. A biosimilar is a biological product that shares many characteristics with a reference biologic and doesn’t exhibit any clinically significant variations in terms of safety, purity, or potency.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of coagulation factor-based compositions. 

Key players in coagulation factor-based compositions – a disruptive innovation in the pharmaceutical industry  

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators. 

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. 

Patent volumes related to coagulation factor-based compositions

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Novo Nordisk Foundation 346 Unlock company profile
Sanofi 325 Unlock company profile
Takeda Pharmaceutical 198 Unlock company profile
Bayer 189 Unlock company profile
Moderna 178 Unlock company profile
Biogen 176 Unlock company profile
LFB 122 Unlock company profile
Children's Hospital of Philadelphia 115 Unlock company profile
Catalyst Biosciences 95 Unlock company profile
Amunix Operating 95 Unlock company profile
Baxter International 93 Unlock company profile
CSL 92 Unlock company profile
Sangamo Therapeutics 75 Unlock company profile
Teva Pharmaceutical Industries 45 Unlock company profile
GLAdiator Biosciences 44 Unlock company profile
Coagulant Therapeutics 39 Unlock company profile
DRK-Blutspendedienst Baden-Wurttemberg-Hessen 34 Unlock company profile
Johnson & Johnson 32 Unlock company profile
Pfizer 31 Unlock company profile
OPKO Health 25 Unlock company profile
F. Hoffmann-La Roche 25 Unlock company profile
PDS Biotechnology 23 Unlock company profile
Nektar Therapeutics 21 Unlock company profile
Alkermes 19 Unlock company profile
Emergent BioSolutions 18 Unlock company profile
Octapharma 17 Unlock company profile
Life Sciences Research Partners VZW 16 Unlock company profile
Regeneron Pharmaceuticals 14 Unlock company profile
Intellia Therapeutics 14 Unlock company profile
Medexus Pharmaceuticals 14 Unlock company profile
Cell Machines 13 Unlock company profile
Hanmi Science 13 Unlock company profile
CNJ Holdings 13 Unlock company profile
BioMarin Pharmaceutical 12 Unlock company profile
Alveron Pharma 12 Unlock company profile
Xenetic Biosciences 12 Unlock company profile
Glycotope 12 Unlock company profile
Alnylam Pharmaceuticals 12 Unlock company profile
Maxygen 12 Unlock company profile
ToolGen 11 Unlock company profile
DRK-Blutspendedienst Ost gemeinnutzige 11 Unlock company profile
SK Chemicals 11 Unlock company profile
Swedish Orphan Biovitrum 11 Unlock company profile
Beehive Capital LLP 10 Unlock company profile
Children's Healthcare of Atlanta 9 Unlock company profile
Poseida Therapeutics 9 Unlock company profile
Eio Biomedical 8 Unlock company profile
CRISPR Therapeutics 7 Unlock company profile
Meiji Holdings 7 Unlock company profile
Octapharma Biopharmaceuticals 7 Unlock company profile

Source: GlobalData Patent Analytics

Novo Nordisk is a leading global healthcare company focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including haemophilia, human growth hormone (HGH) disorders, and obesity. The company has made long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to continually advance the development of novel therapies. Novo Nordisk is dedicated to improving access to quality care for people with haemophilia and rare bleeding disorders in developing and emerging countries. Novo Nordisk has an agreement to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approach for haemophilia.

In terms of application diversity, Alveron Pharma is the top company followed by Cell Machines Inc. and Swedish Orphan Biovitrum AB. By means of geographic reach, PDS Biotechnology Corp holds the top position. Teva Pharmaceutical Industries Ltd and Intellia Therapeutics Inc are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.